Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Genetic prediction of blood metabolites and causal relationships with pain associated with temporomandibular disorders: a Mendelian randomization study
1School of Stomatology, Jiangxi Medical College, Nanchang University, 330006 Nanchang, Jiangxi, China
2Jiangxi Provincial Key Laboratory of Oral Diseases, 330006 Nanchang, Jiangxi, China
3Jiangxi Provincial Clinical Research Center for Oral Diseases, 330006 Nanchang, Jiangxi, China
DOI: 10.22514/jofph.2025.034 Vol.39,Issue 2,June 2025 pp.155-165
Submitted: 29 October 2024 Accepted: 03 January 2025
Published: 12 June 2025
*Corresponding Author(s): Weihong Xi E-mail: xiweihong@ncu.edu.cn
† These authors contributed equally.
Background: This study aims to elucidate the causal relationships between 1400 blood metabolites and pain related to temporomandibular disorders (TMD) using Mendelian Randomization (MR) analysis. Methods: Utilizing data from genome-wide association studies (GWAS), our analysis was conducted with R software using the “TwoSampleMR” package. The primary method applied was Inverse Variance Weighted (IVW) analysis, which was supplemented with MR-Egger, Weighted Median, Simple Mode and Weighted Mode methods to examine the causal impact of blood metabolites on TMD-associated pain. We also assessed heterogeneity and the presence of horizontal pleiotropy using MR-Egger regression, MR-PRESSO (MR Pleiotropy Residual Sum and Outlier) global tests, and MR-Egger intercept tests. Results: Three metabolites—Acetylcarnitine, Propionylcarnitine (c3) and X-24241—were significantly associated with TMD-related pain. Specifically, Acetylcarnitine had an odds ratio (OR) of 1.409 (95% CI (confidence intervals): 1.016–1.954, p = 0.04), Propionylcarnitine (c3) had an OR of 1.194 (95% CI: 1.036–1.377, p = 0.014), and X-24241 had an OR of 1.408 (95%CI: 1.108–1.790, p = 0.005). Conclusions: This study establishes a causal link between increased levels of these three metabolites and TMD-related pain. Our findings provide new insights into the pathogenesis of TMD and potential therapeutic targets.
Blood metabolites; Mendelian randomization; Temporomandibular joint pain; Causal relationships
Xue’e Zhang, Ketong Le, Weihong Xi. Genetic prediction of blood metabolites and causal relationships with pain associated with temporomandibular disorders: a Mendelian randomization study. Journal of Oral & Facial Pain and Headache. 2025. 39(2);155-165.
[1] Velly AM, Anderson GC, Look JO, Riley JL, Rindal DB, Johnson K, et al. Management of painful temporomandibular disorders: methods and overview of the national dental practice-based research network prospective cohort study. Journal of the American Dental Association. 2022; 153: 144–157.
[2] Kapos FP, Exposto FG, Oyarzo JF, Durham J. Temporomandibular disorders: a review of current concepts in aetiology, diagnosis and management. Oral Surgery. 2020; 13: 321–334.
[3] Shrivastava M, Battaglino R, Ye L. A comprehensive review on biomarkers associated with painful temporomandibular disorders. International Journal of Oral Science. 2021; 13: 23.
[4] Wu N, Hirsch C. Temporomandibular disorders in German and Chinese adolescents. Journal of Orofacial Orthopedics. 2010; 71: 187–198.
[5] Qvintus V, Sipila K, Le Bell Y, Suominen AL. Prevalence of clinical signs and pain symptoms of temporomandibular disorders and associated factors in adult Finns. Acta Odontologica Scandinavica. 2020; 78: 515–521.
[6] Xie C, Lin M, Yang H, Ren A. Prevalence of temporomandibular disorders and its clinical signs in Chinese students, 1979–2017: a systematic review and meta-analysis. Oral Diseases. 2019; 25: 1697–1706.
[7] Shimada A, Ishigaki S, Matsuka Y, Komiyama O, Torisu T, Oono Y, et al. Effects of exercise therapy on painful temporomandibular disorders. Journal of Oral Rehabilitation. 2019; 46: 475–481.
[8] Slade GD, Fillingim RB, Sanders AE, Bair E, Greenspan JD, Ohrbach R, et al. Summary of findings from the OPPERA prospective cohort study of incidence of first-onset temporomandibular disorder: implications and future directions. Journal of Pain. 2013; 14: T116–T124.
[9] Yang Q, Vijayakumar A, Kahn BB. Metabolites as regulators of insulin sensitivity and metabolism. Nature Reviews Molecular Cell Biology. 2018; 19: 654–672.
[10] Khoo SC, Shoji Y, Teh CH, Ma NL. Discovery of biomarkers for myogenous temporomandibular disorders through salivary metabolomic profiling: a pilot study. Journal of Oral & Facial Pain and Headache. 2023; 37: 207–216.
[11] Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nature Reviews Molecular Cell Biology. 2016; 17: 451–459.
[12] Wang Z, Chen S, Zhu Q, Wu Y, Xu G, Guo G, et al. Using a two-sample mendelian randomization method in assessing the causal relationships between human blood metabolites and heart failure. Frontiers in Cardiovascular Medicine. 2021; 8: 695480.
[13] Wang Z, Yang Q. The causal relationship between human blood metabolites and the risk of visceral obesity: a Mendelian randomization analysis. Lipids in Health and Disease. 2024; 23: 39.
[14] Sekula P, Del Greco MF, Pattaro C, Köttgen A. Mendelian randomization as an approach to assess causality using observational data. Journal of the American Society of Nephrology. 2016; 27: 3253–3265.
[15] Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA. 2021; 326: 1614–1621.
[16] Yang J, Yan B, Zhao B, Fan Y, He X, Yang L, et al. Assessing the causal effects of human serum metabolites on 5 major psychiatric disorders. Schizophrenia Bulletin. 2020; 46: 804–813.
[17] Burgess S, Swanson SA, Labrecque JA. Are Mendelian randomization investigations immune from bias due to reverse causation? European Journal of Epidemiology. 2021; 36: 253–257.
[18] Guo JZ, Xiao Q, Gao S, Li XQ, Wu QJ, Gong TT. Review of Mendelian randomization studies on ovarian cancer. Frontiers in Oncology. 2021; 11: 681396.
[19] Xu C, Ren X, Lin P, Jin S, Zhang Z. Exploring the causal effects of sleep characteristics on TMD-related pain: a two-sample Mendelian randomization study. Clinical Oral Investigations. 2024; 28: 384.
[20] Chen X, Cheng Z, Xu J, Wang Q, Zhao Z, Jiang Q. Causal effects of educational attainment on temporomandibular disorders and the mediating pathways: a Mendelian randomization study. Journal of Oral Rehabilitation. 2024; 51: 817–826.
[21] Chen X, Cheng Z, Xu J, Wang Q, Zhao Z, Jiang Q. Causal effects of autoimmune diseases on temporomandibular disorders and the mediating pathways: a Mendelian randomization study. Frontiers in Immunology. 2024; 15: 1390516.
[22] Xiang Y, Song J, Liang Y, Sun J, Zheng Z. Causal relationship between psychiatric traits and temporomandibular disorders: a bidirectional two-sample Mendelian randomization study. Clinical Oral Investigations. 2023; 27: 7513–7521.
[23] Chen Y, Lu T, Pettersson-Kymmer U, Stewart ID, Butler-Laporte G, Nakanishi T, et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nature Genetics. 2023; 55: 44–53.
[24] Cheng Q, Yang Y, Shi X, Yeung KF, Yang C, Peng H, et al. MR-LDP: a two-sample Mendelian randomization for GWAS summary statistics accounting for linkage disequilibrium and horizontal pleiotropy. NAR Genomics and Bioinformatics. 2020; 2: lqaa028.
[25] Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. European Journal of Epidemiology. 2017; 32: 377–389.
[26] Du Y, Wang Q, Zheng Z, Zhou H, Han Y, Qi A, et al. Gut microbiota influence on lung cancer risk through blood metabolite mediation: from a comprehensive Mendelian randomization analysis and genetic analysis. Frontiers in Nutrition. 2024; 11: 1425802.
[27] Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genetic Epidemiology. 2016; 40: 304–314.
[28] Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology. 2017; 28: 30–42.
[29] Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genetic Epidemiology. 2013; 37: 658–665.
[30] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International Journal of Epidemiology. 2015; 44: 512–525.
[31] Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature Genetics. 2018; 50: 693–698.
[32] Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base platform supports systematic causal inference across the human phenome. eLife. 2018; 7: e34408.
[33] Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the international RDC/TMD consortium network* and orofacial pain special interest group†. Journal of Oral & Facial Pain and Headache. 2014; 28: 6–27.
[34] Reiter S, Emodi-Perlman A, Kasiel H, Abboud W, Friedman-Rubin P, Arias OW, et al. Headache attributed to temporomandibular disorders: axis I and II findings according to the diagnostic criteria for temporomandibular disorders. Journal of Oral & Facial Pain and Headache. 2021; 35: 119–128.
[35] Nguyen TT, Vanichanon P, Bhalang K, Vongthongsri S. Pain duration and intensity are related to coexisting pain and comorbidities present in temporomandibular disorder pain patients. Journal of Oral & Facial Pain and Headache. 2019; 33: 205–212.
[36] Karamat A, Smith JG, Melek LNF, Renton T. Psychologic impact of chronic orofacial pain: a critical review. Journal of Oral & Facial Pain and Headache. 2022; 36: 103–140.
[37] Jasim H, Ghafouri B, Gerdle B, Hedenberg-Magnusson B, Ernberg M. Altered levels of salivary and plasma pain related markers in temporomandibular disorders. The Journal of Headache and Pain. 2020; 21: 105.
[38] Sorenson A, Hresko K, Butcher S, Pierce S, Tramontina V, Leonardi R, et al. Expression of Interleukin-1 and temporomandibular disorder: contemporary review of the literature. CRANIO®. 2018; 36: 268–272.
[39] Ibi M. Inflammation and temporomandibular joint derangement. Biological and Pharmaceutical Bulletin. 2019; 42: 538–542.
[40] Kringel D, Lippmann C, Parnham MJ, Kalso E, Ultsch A, Lötsch J. A machine-learned analysis of human gene polymorphisms modulating persisting pain points to major roles of neuroimmune processes. European Journal of Pain. 2018; 22: 1735–1756.
[41] Cunha-Oliveira T, Montezinho L, Simoes RF, Carvalho M, Ferreiro E, Silva FSG. Mitochondria: a promising convergent target for the treatment of amyotrophic lateral sclerosis. Cells. 2024; 13: 248.
[42] Pourshahidi S, Shamshiri AR, Derakhshan S, Mohammadi S, Ghorbani M. The effect of Acetyl-L-Carnitine (ALCAR) on peripheral nerve regeneration in animal models: a systematic review. Neurochemical Research. 2023; 48: 2335–2344.
[43] Lucarini E, Micheli L, Toti A, Ciampi C, Margiotta F, Di Cesare Mannelli L, et al. Anti-Hyperalgesic efficacy of Acetyl L-Carnitine (ALCAR) against visceral pain induced by colitis: involvement of glia in the enteric and central nervous system. International Journal of Molecular Sciences. 2023; 24: 14841.
[44] Chiechio S, Nicoletti F. Metabotropic glutamate receptors and the control of chronic pain. Current Opinion in Pharmacology. 2012; 12: 28–34.
[45] Liao ZQ, Han X, Wang YH, Shi J, Zhang Y, Zhao H, et al. Differential metabolites in osteoarthritis: a systematic review and meta-analysis. Nutrients. 2023; 15: 4191.
[46] Longo N, Sass JO, Jurecka A, Vockley J. Biomarkers for drug development in propionic and methylmalonic acidemias. Journal of Inherited Metabolic Disease. 2022; 45: 132–143.
[47] Miettinen T, Nieminen AI, Mantyselka P, Kalso E, Lötsch J. Machine learning and pathway analysis-based discovery of metabolomic markers relating to chronic pain phenotypes. International Journal of Molecular Sciences. 2022; 23: 5085.
Science Citation Index (SCI)
Science Citation Index Expanded (SCIE)
BIOSIS Previews
Scopus: CiteScore 3.1 (2024)
Cumulative Index to Nursing and Allied Health Literature (CINAHL)
Preliminary Review: Typically 1–7 days (median: 5 days)
Peer Review: Typically 4–16 weeks (median: 8.6 weeks)
Notes: Review times may vary depending on manuscript complexity or reviewer availability, with some articles requiring longer than 16 weeks. Your information is kept confidential throughout the review process.
Top